What's really bonkers is "spike targeting" MABs are only likely to be useful for a short while more.. spike changes (new variants) = lower binding affinity

Quote:

---

The US government is no longer distributing Eli Lilly's bamlanivimab into California, Arizona and Nevada because of the prevalence of a viral variant that is not susceptible to the monoclonal antibody, FDA acting commissioner Janet Woodcock told physicians taking part in a webinar with the American Medical Association ...Mar 17, 2021

---